Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Møller

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Ugeskrift for Laeger|March 15, 2019
[Cancer immune therapy for the treatment of haematological malignancies]Morten Orebo Holmström, Uffe Klausen, Nicolai Grønne Jørgensen, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|October 8, 2024
Lymphomas of the submandibular gland: a nationwide cohort studyFahd Al-Shahrestani, Ahmed Ehsan Al-Khafaf, Zain Asheer, et al.
Blood Cancer Journal|October 26, 2023
Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphomaMaja Ludvigsen, Amanda Jessica Campbell, Marie Beck Enemark, et al.
The Laryngoscope|December 17, 2024
Lymphomas of the Parotid Gland in Denmark: A Nationwide Cohort StudyFahd Al-Shahrestani, Ahmed Ehsan Al-Khafaf, Zain Asheer, et al.
Blood|November 16, 2007
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 studyBertrand Coiffier, Stéphane Lepretre, Lars Møller Pedersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2012
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisoneTina Marie Green, Ken H Young, Carlo Visco, et al.
Oncoimmunology|January 9, 2018
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapyShamaila Munir Ahmad, Evelina Martinenaite, Morten Holmström, et al.
British Journal of Haematology|February 26, 2016
Little value of surveillance magnetic resonance imaging for primary CNS lymphomas in first remission: results from a Danish Multicentre StudyKaren Juul Mylam, Thomas Yssing Michaelsen, Martin Hutchings, et al.
British Journal of Haematology|April 23, 2010
Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 studyBertrand Coiffier, Nedjad Losic, Birgitte Biilmann Rønn, et al.
Plos One|March 15, 2014
Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphomaMinna Taskinen, Riku Louhimo, Satu Koivula, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Ugeskrift for Laeger|March 15, 2019
[Cancer immune therapy for the treatment of haematological malignancies]Morten Orebo Holmström, Uffe Klausen, Nicolai Grønne Jørgensen, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|October 8, 2024
Lymphomas of the submandibular gland: a nationwide cohort studyFahd Al-Shahrestani, Ahmed Ehsan Al-Khafaf, Zain Asheer, et al.
Blood Cancer Journal|October 26, 2023
Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphomaMaja Ludvigsen, Amanda Jessica Campbell, Marie Beck Enemark, et al.
The Laryngoscope|December 17, 2024
Lymphomas of the Parotid Gland in Denmark: A Nationwide Cohort StudyFahd Al-Shahrestani, Ahmed Ehsan Al-Khafaf, Zain Asheer, et al.
Blood|November 16, 2007
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 studyBertrand Coiffier, Stéphane Lepretre, Lars Møller Pedersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2012
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisoneTina Marie Green, Ken H Young, Carlo Visco, et al.
Oncoimmunology|January 9, 2018
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapyShamaila Munir Ahmad, Evelina Martinenaite, Morten Holmström, et al.
British Journal of Haematology|February 26, 2016
Little value of surveillance magnetic resonance imaging for primary CNS lymphomas in first remission: results from a Danish Multicentre StudyKaren Juul Mylam, Thomas Yssing Michaelsen, Martin Hutchings, et al.
British Journal of Haematology|April 23, 2010
Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 studyBertrand Coiffier, Nedjad Losic, Birgitte Biilmann Rønn, et al.
Plos One|March 15, 2014
Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphomaMinna Taskinen, Riku Louhimo, Satu Koivula, et al.
Pageof 6